Vedana Therapeutics emerged from stealth with a $46 million Series A to develop its internally discovered antibody programs for migraine prevention. The startup’s pipeline focuses on subcutaneously delivered antibodies targeting the PACAP pathway, alongside efforts that leverage prior clinical expertise across CGRP and PACAP approaches. The company said it is advancing lead programs aimed at long-acting migraine prevention, including an anti-PACAP strategy and a second concept designed to target both PACAP and CGRP simultaneously. The management team highlights a persistent treatment gap, noting that many patients still fail to achieve optimal control. For migraine drug developers and investors, the funding underscores continued appetite for newer mechanisms beyond standard CGRP-targeting approaches.